XBI Stock State Street SPDR S&P Biotech ETF
US · NYSEArcaLast in our picks 2026-10-17 — not in the current list; analysis below is from that screen
Diversified biotechnology exposure captures clinical catalysts while reducing single-company development risk.
Signal breakdown
- ▸Breakthrough clinical data and improving biopharma sentiment support breadth.
- ▾Below 50-day MA (-8.75%)
- ▸Above 200-day MA — long-term uptrend
Is XBI a buy right now?
Trend: XBI is trading below the 50-day average (-4.16%), RSI 49 — neutral momentum, with a 3-month return of +0.54%.
Our screen: BUY (score 2) — Diversified biotechnology exposure captures clinical catalysts while reducing single-company development risk.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +0.30% | +2.80% | +4.10% | +15.80% | -7.10% | +10.50% | -3.00% | -4.50% |
Fundamentals
Technical signals
About State Street SPDR S&P Biotech ETF
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index.
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.